Preliminary clinical pharmacokinetic evaluation of bemotrizinol - A new sunscreen active ingredient being considered for inclusion under FDA's over-the-counter (OTC) sunscreen monograph.

Protection against sunburn, skin damage and the carcinogenic effects of ultraviolet light are the primary health benefits associated with UV filters used in topical sunscreen drug products. Countries such as Europe have 30+ UV filters approved for sunscreen products while the US has about 10, greatly reducing the options to provide diverse, effective sun protection products. Bemotrizinol (BEMT) is the first new sunscreen active ingredient to be evaluated for inclusion in the Over-The-Counter (OTC) sunscreen monograph using FDA's new Generally Recognized as Safe and Effective (GRASE) testing guidelines. An in vitro skin permeation test (IVPT) and clinical pilot pharmacokinetic Maximum Usage Trial (MUsT) were completed to support the GRASE determination for 6% BEMT. IVPT results indicated an oil +10% ethanol as the model sunscreen intervention for the pilot MUsT. The open-label trial revealed: BEMT concentrations rarely exceeded FDA's defined threshold (0.5 ng/mL) in plasma; no evidence for BEMT accumulation or steady-state concentrations above threshold; only one moderate and few mild treatment emergent adverse events (TEAEs). Therefore, maximal topical applications of 6% BEMT in a model sunscreen formulation did not contribute to meaningful systemic exposure. These results support the safety of BEMT 6% for human sunscreen use.

Triclosan and thyroid-mediated metamorphosis in anurans: differentiating growth effects from thyroid-driven metamorphosis in Xenopus laevis.

In a previously reported study, we used a standard metamorphosis anuran model to assess potential effect of the antibacterial agent triclosan (TCS) on normal prometamorphic Xenopus laevis. Results indicated that environmentally relevant TCS concentrations did not alter the normal course of thyroid-mediated metamorphosis in this standard anuran model. However, to examine potential effects of TCS exposure during premetamorphosis and to distinguish between effects on metamorphosis and effects on growth, a longer term TCS exposure study was conducted. Standard Nieuwkoop and Faber (NF) stage 47 X. laevis larvae were exposed for 32 days (ca. NF stage 59-60) via flow-through to four different concentrations of TCS: < 0.2 (control), 0.8, 3.1, 12.5, or 50.0 µg TCS/l. Primary endpoints were survival, hind limb length, body length (whole; snout-to-vent), developmental stage, wet whole body weight, thyroid histology, plasma thyroid hormone (TH) concentrations, TH receptor beta (TRß), and type II and III deiodinase (DI-2 and DI-3) expression. Endpoints measured to evaluate effects on thyroid-mediated metamorphosis including developmental stage, thyroid histology, TRß expression, DI-2 and DI-3 expression, and thyroid gland 3,5,3',5'-tetraiodothyronine (T4) and plasma T4 and 3,5,3'-triiodothyronine (T3) levels were not affected by TCS exposure. However, increased larval growth based on whole body length (0.78, 12.5, and 50 µg TCS/l), snout-vent length (3.1 and 12.5 µg TCS/l), and whole body weight (0.8, 12.5, and 50.0 µg TCS/l) was observed following 32-day TCS exposure. These results indicated that TCS exposure during pre- and prometamorphosis increased larval growth but did not alter the normal course of metamorphosis in X. laevis. The increased growth associated with TCS exposure was not unexpected and is generally consistent with the presence of reduced bacterial stressors in culture.

Triclosan and anuran metamorphosis: no effect on thyroid-mediated metamorphosis in Xenopus laevis.

Nieuwkoop and Faber stage 51 Xenopus laevis larvae were exposed for 21 days to four different concentrations of triclosan (TCS): <0.2 (control), 0.6, 1.5, 7.2, or 32.3 microg TCS/l. Primary endpoints were survival, hind limb length, body length (whole; snout to vent), developmental stage, wet whole body weight, and thyroid histology. Thyroid hormone (TH) concentrations were determined in whole thyroid and plasma samples from stage-matched exposure day 21 specimens. TH receptor-beta (TRbeta) expression was measured in stage-matched tail fin tissue samples collected at exposure days 0 and 21. Reduced larval growth occurred at exposure day 21 with 1.5 microg/l treatment. Larval developmental stage at exposure day 21 was not significantly different from controls based on observed parameters. Thyroid histology was not affected by TCS, and thyroxine (T4) levels in thyroid glands or plasma were not different from controls. A concentration-dependent increase in TRbeta expression in exposure day 21 larvae was not detected. However, increased expression was found in stage-matched larvae exposed to 1.5 or 7.2 microg TCS/l. Our study indicates that environmentally relevant TCS concentrations do not alter the normal course of thyroid-mediated metamorphosis in this standard anuran model.